Yutaka Kawabata1, Takeshi Soeki1, Hiroyuki Ito1, Tomomi Matsuura1, Kenya Kusunose1, Takayuki Ise1, Koji Yamaguchi1, Takeshi Tobiume1, Shusuke Yagi1, Daiju Fukuda2, Hirotsugu Yamada3, Tetsuzo Wakatsuki1, Mitsuhiro Kitani4, Kazuhiro Kawano5, Yoshio Taketani6, Masataka Sata1. 1. Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan. 2. Department of Cardio-Diabetes Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan. 3. Department of Community Medicine for Cardiology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan. 4. Department of Cardiovascular Medicine, Kagawa Prefectural Shirotori Hospital, Higashikagawa, Japan. 5. Department of Cardiovascular Medicine, Yoshinogawa Medical Center, Yoshinogawa, Japan. 6. Department of Cardiovascular Medicine, Shikoku Medical Center for Children and Adults, Zentsuji, Japan.
Abstract
OBJECTIVES: Cilnidipine, an L-/N-type calcium channel blocker (CCB), has unique organ-protective properties due to suppression of hyperactivity in the sympathetic nervous system and renin-angiotensin system (RAS). In this study, we hypothesized that cilnidipine might exert a renoprotective effect by suppressing the RAS. METHODS: A total of 25 hypertensive patients receiving a RAS inhibitor were randomly assigned to a cilnidipine (n = 12) or amlodipine (n = 13) group. The effects of cilnidipine on proteinuria and angiotensin II-renin feedback were assessed. RESULTS: After 6 months of treatment, both systolic and diastolic blood pressures were significantly reduced to a similar extent in both groups. The urine albumin-to-creatinine ratio was significantly lower in the cilnidipine group (p < 0.05) than in the amlodipine group. Amlodipine increased plasma angiotensin I and angiotensin II levels (p < 0.05), whereas cilnidipine did not. Interestingly, the cilnidipine group had a higher ratio of angiotensin-(1-7) (Ang-(1-7)) to angiotensin II in plasma than the amlodipine group (p < 0.05). CONCLUSIONS: The L-/N-type CCB cilnidipine, but not amlodipine, decreased urinary albumin excretion in hypertensive patients. Cilnidipine also increased the ratio of Ang-(1-7) to angiotensin II in plasma, which might be one factor underlying its beneficial effects.
OBJECTIVES: Cilnidipine, an L-/N-type calcium channel blocker (CCB), has unique organ-protective properties due to suppression of hyperactivity in the sympathetic nervous system and renin-angiotensin system (RAS). In this study, we hypothesized that cilnidipine might exert a renoprotective effect by suppressing the RAS. METHODS: A total of 25 hypertensive patients receiving a RAS inhibitor were randomly assigned to a cilnidipine (n = 12) or amlodipine (n = 13) group. The effects of cilnidipine on proteinuria and angiotensin II-renin feedback were assessed. RESULTS: After 6 months of treatment, both systolic and diastolic blood pressures were significantly reduced to a similar extent in both groups. The urine albumin-to-creatinine ratio was significantly lower in the cilnidipine group (p < 0.05) than in the amlodipine group. Amlodipine increased plasma angiotensin I and angiotensin II levels (p < 0.05), whereas cilnidipine did not. Interestingly, the cilnidipine group had a higher ratio of angiotensin-(1-7) (Ang-(1-7)) to angiotensin II in plasma than the amlodipine group (p < 0.05). CONCLUSIONS: The L-/N-type CCB cilnidipine, but not amlodipine, decreased urinary albumin excretion in hypertensive patients. Cilnidipine also increased the ratio of Ang-(1-7) to angiotensin II in plasma, which might be one factor underlying its beneficial effects.
Authors: Ana Cristina Simões e Silva; Sérgio Veloso Brant Pinheiro; Regina Maria Pereira; Anderson José Ferreira; Robson Augusto Souza Santos Journal: Mini Rev Med Chem Date: 2006-05 Impact factor: 3.862
Authors: Ping Xu; Andrey C Costa-Goncalves; Mihail Todiras; Luiza A Rabelo; Walkyria O Sampaio; Marina M Moura; Sergio Sousa Santos; Friedrich C Luft; Michael Bader; Volkmar Gross; Natalia Alenina; Robson A S Santos Journal: Hypertension Date: 2008-01-07 Impact factor: 10.190
Authors: Ibrahim F Benter; Mariam H M Yousif; Constantin Cojocel; May Al-Maghrebi; Debra I Diz Journal: Am J Physiol Heart Circ Physiol Date: 2007-01 Impact factor: 4.733
Authors: M Donoghue; F Hsieh; E Baronas; K Godbout; M Gosselin; N Stagliano; M Donovan; B Woolf; K Robison; R Jeyaseelan; R E Breitbart; S Acton Journal: Circ Res Date: 2000-09-01 Impact factor: 17.367
Authors: Jasmina Varagic; Aaron J Trask; Jewell A Jessup; Mark C Chappell; Carlos M Ferrario Journal: J Mol Med (Berl) Date: 2008-04-25 Impact factor: 4.599